Omnicare: Court Approves GenieRx 363 Sale of CVS Pharmacy Unit
Omnicare's Texas bankruptcy court approved the 363 sale of the CVS long-term care pharmacy unit to GenieRx Holdings on May 13, 2026, after a $948.8M False Claims Act judgment; the auction was canceled and plan exclusivity extended to July 2026.
Omnicare, LLC—a long-term care pharmacy provider and a subsidiary of CVS Health Corporation since a $12.7 billion acquisition in 2015—filed chapter 11 petitions on September 22, 2025 in the U.S. Bankruptcy Court for the Northern District of Texas (Dallas Division), case number 8:25-bk-80486, following a $948.8 million False Claims Act judgment that the company characterized as "extreme and unconstitutional." The bankruptcy encompasses 111 debtor entities serving more than 800,000 patients annually across 4,000+ skilled nursing facilities, assisted living communities, and other long-term care settings in 47 states. Omnicare secured $110 million in debtor-in-possession financing from JMB Capital Partners to fund a 363 sale process that resolved without an auction.
On May 13, 2026, the bankruptcy court approved the sale of substantially all assets to GenieRx Holdings LLC for a reported $250 million. GenieRx had been designated the stalking horse bidder and became the successful bidder after Omnicare canceled its scheduled auction for lack of a competing qualified bid. The same day, the court extended the debtors' exclusive periods to file and solicit a chapter 11 plan, keeping plan negotiations with the U.S. Government, CVS, and the creditors' committee on a track separate from the now court-approved sale. The judgment that triggered the case stemmed from a 2015 whistleblower lawsuit alleging that Omnicare dispensed medications without valid prescriptions or refills from 2010 to 2018, then billed Medicare, Medicaid, and TRICARE for over 3.3 million false claims.
| Debtor(s) | Omnicare, LLC, et al. (111 debtors; jointly administered) |
| Court | U.S. Bankruptcy Court, Northern District of Texas (Dallas Division) |
| Case Number | 8:25-bk-80486 |
| Judge | Hon. Stacey G. C. Jernigan |
| Petition Date | September 22, 2025 |
| DIP Facility | $110 million from JMB Capital Partners; $25 million interim draw; amended maturity August 31, 2026 |
| Sale Order | Entered May 13, 2026; buyer GenieRx Holdings LLC; reported $250 million |
| Exclusive Filing Period | Extended to July 20, 2026 |
| Table: Case Snapshot |
Open the public case profile for docket context, hearings, advisors, and plan updates.
From $12.7 Billion CVS Acquisition to Bankruptcy
The CVS acquisition. On May 21, 2015, CVS Health and Omnicare announced a definitive agreement under which CVS would acquire Omnicare for $98.00 per share in cash. CVS completed the acquisition on August 18, 2015 for approximately $12.9 billion total enterprise value—$10.4 billion in cash plus assumption of $2.3 billion in debt.
Serial impairments. In August 2018, CVS announced a $3.9 billion goodwill impairment charge—representing 59% of Omnicare's recorded value. In February 2019, CVS recorded an additional $2.2 billion impairment due to "further deterioration expected in the business." In 2021, a $431 million impairment charge eliminated remaining goodwill. By the third quarter of 2022, CVS reported a $2.5 billion loss related to Omnicare and declared the long-term care pharmacy business "no longer a strategic asset." Cumulative impairments exceeded $6 billion—more than half the original purchase price—before the bankruptcy filing.
Failed sale attempt. CVS's November 2022 announcement that it planned to sell Omnicare followed a determination that the carrying value of the LTC business exceeded its fair value. CVS halted those sale efforts in 2023 without completing a transaction, before the False Claims Act judgment in 2025.
The $948.8 Million False Claims Act Judgment
Prior settlements and compliance history. Omnicare's compliance record included earlier False Claims Act settlements: nearly $50 million in 2012 over kickback allegations, $124 million in 2014 for improper financial incentives to nursing homes, $28.125 million in 2016 to resolve allegations that it solicited kickbacks from Abbott Laboratories in exchange for promoting Depakote for nursing home patients (payments allegedly disguised as "grants" and "educational funding"), and $8 million in 2017 to settle FCA allegations with the U.S. Attorney for the District of New Jersey, DOJ, and 28 states over billing for generic drugs different from those dispensed and dispensing drugs with patient-specific labels displaying incorrect manufacturer or NDC information.
The Bassan whistleblower lawsuit. In 2015, the same year CVS completed its acquisition, former Omnicare pharmacist Uri Bassan filed a qui tam lawsuit under the False Claims Act's whistleblower provisions. The lawsuit alleged that Omnicare dispensed prescription medications without valid prescriptions or refills from 2010 to 2018, with pharmacies assigning new prescription numbers without required paperwork and pharmacist approvals after original prescriptions expired or ran out of refills. The company billed Medicare, Medicaid, and TRICARE for these dispensed medications. In 2019, the U.S. Government intervened in the lawsuit, and as the qui tam relator Bassan is entitled to 15–25% of any recovery.
The April 2025 verdict and July 2025 judgment. After a four-week trial in the Southern District of New York, a federal jury in April 2025 found Omnicare liable for 3,341,032 false claims over eight years, described by the U.S. Attorney for the Southern District of New York as one of the largest damages awards by a jury in a False Claims Act case. Judge Colleen McMahon issued her ruling on July 7, 2025, imposing a total judgment of approximately $948.8 million: $135.6 million in single damages, $406.8 million in trebled damages, and $542 million in statutory penalties against Omnicare. CVS was found responsible for approximately 30% of the false claims—1,016,039 claims submitted after the August 2015 acquisition—and was held jointly and severally liable for $164.8 million of the judgment. The court found that "Omnicare was aware for years of the problems posed by its dispensing practices" yet failed to implement corrective measures.
Constitutional challenges and penalty proportionality. Judge McMahon acknowledged that strict application of the FCA's $5,000-per-violation penalty would have yielded approximately $26.9 billion. The court rejected Omnicare's argument that penalties should be limited to a 1:1 ratio with damages, finding that "a 4:1 ratio was constitutionally permissible" under the Eighth Amendment's Excessive Fines Clause, and clarified that "the Eighth Amendment's Excessive Fines Clause, rather than due process concerns, governs the constitutionality of FCA penalties." Omnicare's President David Azzolina characterized the penalty as "extreme and, we believe, unconstitutional," noting that there were "no allegations of harm to any Omnicare patients." In August 2025, a federal judge denied Omnicare's motion to overturn the judgment.
Long-Term Care Pharmacy Duopoly and Customer Distress
Market structure and consolidation. The long-term care pharmacy market totals approximately $18–$19 billion, with national long-term care pharmacies controlling over 90% of market share. Omnicare and PharMerica together comprise over 90% of the skilled nursing facility pharmacy market. A 2023 study of 75 skilled nursing facilities in Rhode Island found that 68 facilities (91%) were served by either Omnicare (43%) or PharMerica (48%), with only 7 facilities (9%) served by other LTC pharmacies. The U.S. institutional pharmacies industry totals $24.8 billion in 2025, with Omnicare and PharMerica identified as the largest companies in the industry.
Reimbursement pressures and industry headwinds. The First Day Declaration identifies factors that compounded Omnicare's financial distress beyond the False Claims Act judgment: lasting COVID-19 impacts on skilled nursing facility occupancy, inflation across the pharmacy supply chain, a tighter labor market, and evolving Medicare policies and declining reimbursement rates from payors. The shift from traditional Medicare to Medicare Advantage, combined with inadequate Medicaid funding, has resulted in revenue not keeping pace with higher costs for skilled nursing operators. CMS finalized a 4.2% increase in Medicare payments to skilled nursing facilities for fiscal year 2025, translating to approximately $1.4 billion in additional Medicare Part A payments.
Customer distress: the Genesis Healthcare bankruptcy. Genesis Healthcare filed chapter 11 on July 9, 2025 with $2.3 billion in debt, affecting over 15,000 residents and 27,000 employees across 200 skilled nursing facilities and senior living centers in 18 states. Genesis faced more than 200 malpractice and wrongful death lawsuits and was spending $8 million monthly to litigate and settle cases before bankruptcy. The First Day Declaration identifies customer bankruptcies as contributors to Omnicare's bad debt and revenue erosion.
DIP Financing and the JMB Capital Facility
DIP financing structure. The debtors secured $110 million in aggregate DIP financing from JMB Capital Partners to fund operations and the sale process. The financing was structured in two tranches: $25 million available upon the September 24, 2025 DIP Interim Order and $85 million upon the November 3, 2025 DIP Final Order.
| DIP Term | Details |
|---|---|
| Total Facility Size | $110 million |
| Interim Amount | $25 million |
| Final Amount | $85 million |
| Type | Non-amortizing, priming super-priority senior secured |
| Interest Rate | 10% per annum, payable monthly in arrears |
| Default Rate | Additional 2% per annum |
| Commitment Fee | 2.0% of commitments ($2.2 million) |
| Exit Fee | 6% of interim and delayed-draw commitments |
| Maturity | August 31, 2026; conditional September 30, 2026 extension if regulatory approvals delay an acceptable sale |
The February 25, 2026 DIP amendment order extended the maturity from June 30, 2026 to August 31, 2026, with a conditional September 30, 2026 extension if regulatory approvals delay an acceptable sale. The same amendment extended the stalking horse milestone from January 31, 2026 to March 31, 2026 and increased the exit fee from 5% to 6% of the interim and delayed-draw commitments. The amendment cited the complexity of the sale process and the need for prospective buyers to complete due diligence; by late January 2026, more than 60 parties had executed non-disclosure agreements, with several engaged in second-round diligence.
GenieRx 363 Sale and Court-Approved Asset Purchase
Bidding procedures and the stalking horse path. Judge Jernigan entered the Bidding Procedures Order on December 3, 2025, authorizing a sale of substantially all assets and permitting the debtors to designate one or more stalking horse bidders. On April 14, 2026, the court entered an order modifying the bid procedures, replacing the original procedures in their entirety and authorizing bid protections capped at a 3% break-up fee and $1.5 million in expense reimbursement, with no protections available to the DIP lender if it served as stalking horse solely through a credit bid. Omnicare then entered a stalking horse asset purchase agreement with GenieRx Holdings, reported by Bloomberg Law as GenieRx Holdings LLC, a partnership between Milrose Capital LLC and Integro Asset Management LLC.
Auction cancellation. On May 1, 2026, Omnicare filed a notice canceling the auction that had been scheduled for May 5, 2026. The debtors determined, in consultation with the consultation parties, that no auction would be held because no competing qualified bid was received; the GenieRx stalking horse bid was designated the successful bid in lieu of an auction. The debtors proceeded directly to a sale hearing on the GenieRx agreement.
The May 13, 2026 sale order. After a sale hearing held May 13, 2026, the court entered the order approving the GenieRx asset purchase agreement and authorizing the sale of substantially all of the debtors' assets free and clear of liens, claims, interests, and encumbrances under section 363(f). The court found that entering into the agreement and consummating the sale was a "valid and reasonable exercise of the Debtors' business judgment," that GenieRx is a "good-faith purchaser within the meaning of section 363(m)" entitled to the protections afforded thereunder, and that the marketing process "afforded a full, fair, and reasonable opportunity for any Potential Bidder to make a higher or otherwise better offer." The order also authorizes the assumption and assignment of executory contracts and unexpired leases to GenieRx under section 365, with cure costs payable upon closing. Reuters and trade press reported the transaction as a $250 million sale; the sale order itself does not state a purchase-price figure, characterizing the consideration only as "fair and reasonable" and constituting "reasonably equivalent value."
No formal objection. The debtors' Certificate of Counsel Regarding Proposed Sale Order, filed May 13, 2026, states that no party in interest filed a formal objection to approval of the sale. The debtors received informal "Sale Order Responses" and requested edits from various interested parties and resolved all of them through revisions to the proposed order, submitting a revised proposed order with a redline comparison. CVS Health said the transaction is expected to close later this year subject to regulatory approvals; the sale order confirms closing remains subject to the regulatory approvals and other conditions set forth in the asset purchase agreement.
Privacy expert declaration. Because the sale transfers patient data, the debtors filed the Declaration of Marcy Wilder, a privacy expert and attorney at Hogan Lovells LLP, in support of the sale motion. Wilder examined Omnicare's Website, MyOmniview, Omniview, and Workforce privacy policies and its HIPAA Notice of Privacy Practices, and concluded that the transfer of personally identifiable information and protected health information to GenieRx is consistent with the company's privacy policies in effect as of the petition date—each of which permitted transfer of information in a bankruptcy or corporate transaction. She concluded that the sale does not necessitate appointment of a consumer privacy ombudsman. Omnicare retained Hogan Lovells as special privacy counsel for the sale process.
Plan Exclusivity and the U.S. Government Claim
Extended exclusive periods. On April 16, 2026, the debtors moved to extend the exclusive periods to file and solicit a chapter 11 plan by 90 days, arguing that allowing competing plans during the sale process would be premature and detrimental. The court granted the motion on May 13, 2026, extending the exclusive filing period to July 20, 2026 and the exclusive solicitation period to September 17, 2026; no objection was filed. The debtors said they were negotiating a consensual plan with key stakeholders—the United States regarding the FCA judgment and appeal, parent company CVS Health, and the creditors' committee—and needed time to evaluate the general unsecured claims pool, resolve personal injury claims, and assess the effect of contract and lease dispositions on claims. A separate order entered the same day extended the debtors' deadline to remove civil actions to August 19, 2026.
The U.S. Government claim. On December 22, 2025, the United States filed a motion seeking approval of a stipulation regarding its False Claims Act claims—the $948.8 million judgment that triggered the bankruptcy and the largest claim in the case. Because the government intervened in the qui tam lawsuit, Uri Bassan is entitled to 15–25% of any recovery under the False Claims Act's relator provisions. CVS was found jointly and severally liable for $164.8 million of the judgment; the parent company remains outside the bankruptcy and solvent, and the government can pursue collection from CVS independent of the bankruptcy estate.
Professional retentions. The debtors retained Jenner & Block LLP as lead bankruptcy counsel, with Haynes and Boone LLP as co-counsel, Williams & Connolly LLP and Dechert LLP as special counsel, Houlihan Lokey Capital as investment banker, Alvarez & Marsal North America and KPMG LLP as financial advisors, and Stretto, Inc. as claims and noticing agent. The Official Committee of Unsecured Creditors retained Herbert Smith Freehills Kramer and Vartabedian Katz Hester & Haynes LLP as co-counsel, with Dundon Advisers and Huron Consulting Services as financial advisors.
First Day Relief, Joint Administration, and Bar Date
The court entered a Joint Administration Order on September 24, 2025, consolidating the 111 debtor entities for procedural purposes while preserving their separate legal identities. The interim DIP order on the same date provided immediate access to $25 million in liquidity. First day relief included authorization to continue existing cash management systems, pay prepetition employee wages and benefits, and maintain critical vendor relationships.
Bar date procedures were established through a December 3, 2025 Bar Date Order after resolving an objection filed on December 1, 2025, setting a February 2, 2026 general bar date and a March 23, 2026 governmental bar date. Stay relief motions have been filed and resolved through agreed stipulations with facility operators.
Key Timeline
| Date | Event |
|---|---|
| May 21, 2015 | CVS announces Omnicare acquisition for $12.7B |
| August 18, 2015 | CVS completes Omnicare acquisition |
| 2015 | Uri Bassan files whistleblower False Claims Act lawsuit |
| August 2018 | CVS announces $3.9B impairment charge (59% of Omnicare value) |
| February 2019 | CVS records $2.2B additional impairment charge |
| 2019 | U.S. Government intervenes in FCA lawsuit |
| 2021 | CVS records $431M impairment eliminating remaining goodwill |
| Q3 2022 | CVS reports $2.5B loss on Omnicare; declares "no longer a strategic asset" |
| November 2022 | CVS announces plan to sell Omnicare |
| 2023 | CVS abandons Omnicare sale efforts |
| April 2025 | Jury finds Omnicare liable for 3,341,032 false claims |
| July 7, 2025 | Judge McMahon issues $948.8 million FCA judgment |
| July 9, 2025 | Genesis Healthcare files chapter 11 (major Omnicare customer) |
| August 2025 | Federal judge denies motion to overturn judgment |
| September 22, 2025 | Chapter 11 petitions filed (111 Debtors) |
| September 24, 2025 | Joint administration order; DIP interim order ($25M) |
| November 3, 2025 | DIP final order entered ($110M total) |
| December 3, 2025 | Bidding procedures order entered; bar date order entered |
| December 22, 2025 | U.S. Government stipulation motion filed |
| February 25, 2026 | DIP amendment order entered, extending sale milestones |
| April 1, 2026 | Omnicare announces GenieRx stalking horse asset purchase agreement |
| April 14, 2026 | Court enters order modifying the bid procedures |
| April 16, 2026 | Debtors move to extend plan exclusivity periods |
| May 1, 2026 | Omnicare cancels auction; GenieRx designated successful bidder |
| May 4, 2026 | Declaration of privacy expert Marcy Wilder filed |
| May 13, 2026 | Sale hearing held; court approves GenieRx asset purchase agreement |
| May 13, 2026 | Court extends exclusive filing period to July 20, 2026 |
| August 31, 2026 | Amended DIP maturity date |
| September 17, 2026 | Extended exclusive solicitation period |
Frequently Asked Questions
Why did Omnicare file for bankruptcy?
Omnicare filed chapter 11 after a federal court in July 2025 imposed a $948.8 million judgment against the company for False Claims Act violations. The judgment stemmed from a 2015 whistleblower lawsuit alleging that Omnicare dispensed medications without valid prescriptions from 2010 to 2018 and billed Medicare, Medicaid, and TRICARE for over 3.3 million false claims. After courts denied Omnicare's attempts to overturn or reduce the judgment, the company filed for bankruptcy to address the liability while preserving the operating business.
Who is buying Omnicare and how much did the sale fetch?
The bankruptcy court approved the sale of substantially all of Omnicare's assets to GenieRx Holdings LLC on May 13, 2026. Bloomberg Law reported GenieRx as a partnership between Milrose Capital LLC and Integro Asset Management LLC and described the transaction as a $250 million sale. The sale order itself does not state a purchase price; it describes the consideration as "fair and reasonable." The transaction is expected to close later in 2026, subject to regulatory approvals.
What happened at the Omnicare auction?
There was no auction. Omnicare designated GenieRx Holdings as the stalking horse bidder and, after receiving no competing qualified bid, canceled the auction that had been scheduled for May 5, 2026. The GenieRx stalking horse bid was designated the successful bid in lieu of an auction, and the debtors proceeded directly to a sale hearing on May 13, 2026.
Did anyone object to the Omnicare sale?
No. The debtors' Certificate of Counsel Regarding Proposed Sale Order states that no party in interest filed a formal objection to approval of the sale. The debtors received informal "Sale Order Responses" and requested edits from interested parties and resolved all of them through revisions to the proposed sale order before the May 13, 2026 hearing.
What was the False Claims Act violation?
A jury found that Omnicare dispensed medications without valid prescriptions or refills from 2010 to 2018. The company allegedly assigned new prescription numbers without required paperwork and pharmacist approvals after original prescriptions expired or ran out of refills, then billed government healthcare programs for the dispensed drugs. The jury found 3,341,032 separate false claims over the eight-year period. There were no allegations of patient harm—patients received the medications they needed, but the claims lacked proper legal authorization.
How large is the bankruptcy case?
The case includes 111 jointly administered debtor entities. Omnicare serves more than 800,000 patients annually across 4,000+ long-term care facilities in 47 states. Court filings show assets between $100 million and $500 million and liabilities between $1 billion and $10 billion. The liabilities reflect the False Claims Act judgment.
Why did the court extend Omnicare's plan exclusivity?
The court extended the exclusive periods on May 13, 2026—the filing period to July 20, 2026 and the solicitation period to September 17, 2026. Omnicare argued that allowing competing plans during the sale process would be premature and that it needed time to negotiate a consensual chapter 11 plan with the United States, CVS Health, and the creditors' committee and to evaluate the general unsecured claims pool. No party objected to the extension.
Will Omnicare's pharmacy services continue?
Yes. Omnicare committed to maintaining uninterrupted pharmacy services and continuing employee wages and benefits throughout the bankruptcy process. The company operated while pursuing the sale, and the GenieRx transaction is structured as a going-concern sale of substantially all assets, including pharmacy locations, customer contracts, and technology systems.
Is CVS Health also in bankruptcy?
No. CVS Health Corporation remains solvent and outside the bankruptcy. Omnicare filed as a separate subsidiary, while CVS was found jointly and severally liable for approximately $164.8 million of the judgment related to false claims submitted after the 2015 acquisition, and that exposure remains regardless of the Omnicare bankruptcy outcome.
What happens to the U.S. Government's $948.8 million claim?
The U.S. Government is the largest creditor in the bankruptcy case. On December 22, 2025, the government filed a motion seeking approval of a stipulation regarding its False Claims Act claims. The claim remains to be addressed through a chapter 11 plan; the debtors said they are negotiating a consensual plan with the United States. The whistleblower who filed the original lawsuit, Uri Bassan, is entitled to 15-25% of any government recovery.
Related Coverage
- Partners Pharmacy: Loan-to-Own Restructuring in the LTC Pharmacy Sector
- Rite Aid: Two Chapter 11 Filings End in Complete Liquidation
- Steward Health Care: $9.2B Collapse and Largest Hospital System Bankruptcy
- Nostrum Laboratories: Liquidation and ANDA Portfolio Sale
This article was researched and written with AI assistance, using court filings, public records, and news sources. AI-generated content can contain errors. Verify all information against primary sources before relying on it. This is not legal or financial advice. Read our full disclaimer.
Get briefings like this by email
New chapter 11 filings and key developments. Unsubscribe anytime.